APO Research
Talk to an analyst

APO RESEARCH · REPORT

Choroidal Neovascularization Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Choroidal Neovascularization Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025198 pages

Choose your research edition.

Industry ResearchChoroidal Neovascularization Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Choroidal Neovascularization Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Choroidal Neovascularization Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Choroidal Neovascularization Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Choroidal Neovascularization Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Choroidal Neovascularization Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Choroidal Neovascularization Drug include Eli Lilly and Company, Soligenix, Inc., RxBio, Inc., RedHill Biopharma Ltd., RDD Pharma Ltd., ProCertus BioPharm Inc., Pluristem Therapeutics Inc., PharmaIN Corporation and Onconova Therapeutics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Choroidal Neovascularization Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Choroidal Neovascularization Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Choroidal Neovascularization Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Choroidal Neovascularization Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Choroidal Neovascularization Drug Segment by Company

Eli Lilly and Company

Soligenix, Inc.

RxBio, Inc.

RedHill Biopharma Ltd.

RDD Pharma Ltd.

ProCertus BioPharm Inc.

Pluristem Therapeutics Inc.

PharmaIN Corporation

Onconova Therapeutics, Inc.

Neumedicines Inc.

Meabco A/S

INSYS Therapeutics, Inc.

Humanetics Corporation

GNI Group Ltd.

Diffusion Pharmaceuticals Inc.

Cumberland Pharmaceuticals, Inc.

Cleveland BioLabs, Inc.

Chrysalis BioTherapeutics, Inc.

Cellphire, Inc.

Choroidal Neovascularization Drug Segment by Type

EWA-001

Entolimod

DG-3

BBT-007

BB-3

AVMOC-001

Others

Choroidal Neovascularization Drug Segment by Application

Clinic

Hospital

Others

Choroidal Neovascularization Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Choroidal Neovascularization Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Choroidal Neovascularization Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Choroidal Neovascularization Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Choroidal Neovascularization Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Choroidal Neovascularization Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Choroidal Neovascularization Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Choroidal Neovascularization Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Choroidal Neovascularization Drug Industry Trends Table 2. Choroidal Neovascularization Drug Industry Drivers Table 3. Choroidal Neovascularization Drug Industry Opportunities and Challenges Table 4. Choroidal Neovascularization Drug Industry Restraints Table 5. Global Choroidal Neovascularization Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Choroidal Neovascularization Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Choroidal Neovascularization Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers Table 9. Global Choroidal Neovascularization Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Choroidal Neovascularization Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Choroidal Neovascularization Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Choroidal Neovascularization Drug Manufacturers, Product Type & Application Table 13. Global Choroidal Neovascularization Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Choroidal Neovascularization Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of EWA-001 Table 17. Major Manufacturers of Entolimod Table 18. Major Manufacturers of DG-3 Table 19. Major Manufacturers of BBT-007 Table 20. Major Manufacturers of BB-3 Table 21. Major Manufacturers of AVMOC-001 Table 22. Major Manufacturers of Others Table 23. Global Choroidal Neovascularization Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 25. Global Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 26. Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2026) Table 27. Global Choroidal Neovascularization Drug Sales Market Share by Type (2027-2032) Table 28. Global Choroidal Neovascularization Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 29. Global Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (K Units) Table 30. Global Choroidal Neovascularization Drug Revenue by Type (2027-2032) & (K Units) Table 31. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2026) Table 32. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Others Table 36. Global Choroidal Neovascularization Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 38. Global Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 39. Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2026) Table 40. Global Choroidal Neovascularization Drug Sales Market Share by Application (2027-2032) Table 41. Global Choroidal Neovascularization Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (K Units) Table 43. Global Choroidal Neovascularization Drug Revenue by Application (2027-2032) & (K Units) Table 44. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2026) Table 45. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2027-2032) Table 46. Global Choroidal Neovascularization Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Choroidal Neovascularization Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Choroidal Neovascularization Drug Sales Market Share by Region (2021-2026) Table 49. Global Choroidal Neovascularization Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Choroidal Neovascularization Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Choroidal Neovascularization Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 53. North America Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 54. Europe Choroidal Neovascularization Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 56. Europe Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Choroidal Neovascularization Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Choroidal Neovascularization Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Choroidal Neovascularization Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Choroidal Neovascularization Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Choroidal Neovascularization Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2021-2026) Table 67. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2027-2032) Table 68. Eli Lilly and Company Company Information Table 69. Eli Lilly and Company Business Overview Table 70. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio Table 72. Eli Lilly and Company Recent Development Table 73. Soligenix, Inc. Company Information Table 74. Soligenix, Inc. Business Overview Table 75. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio Table 77. Soligenix, Inc. Recent Development Table 78. RxBio, Inc. Company Information Table 79. RxBio, Inc. Business Overview Table 80. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio Table 82. RxBio, Inc. Recent Development Table 83. RedHill Biopharma Ltd. Company Information Table 84. RedHill Biopharma Ltd. Business Overview Table 85. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 87. RedHill Biopharma Ltd. Recent Development Table 88. RDD Pharma Ltd. Company Information Table 89. RDD Pharma Ltd. Business Overview Table 90. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 92. RDD Pharma Ltd. Recent Development Table 93. ProCertus BioPharm Inc. Company Information Table 94. ProCertus BioPharm Inc. Business Overview Table 95. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio Table 97. ProCertus BioPharm Inc. Recent Development Table 98. Pluristem Therapeutics Inc. Company Information Table 99. Pluristem Therapeutics Inc. Business Overview Table 100. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio Table 102. Pluristem Therapeutics Inc. Recent Development Table 103. PharmaIN Corporation Company Information Table 104. PharmaIN Corporation Business Overview Table 105. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio Table 107. PharmaIN Corporation Recent Development Table 108. Onconova Therapeutics, Inc. Company Information Table 109. Onconova Therapeutics, Inc. Business Overview Table 110. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 112. Onconova Therapeutics, Inc. Recent Development Table 113. Neumedicines Inc. Company Information Table 114. Neumedicines Inc. Business Overview Table 115. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio Table 117. Neumedicines Inc. Recent Development Table 118. Meabco A/S Company Information Table 119. Meabco A/S Business Overview Table 120. Meabco A/S Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Meabco A/S Choroidal Neovascularization Drug Product Portfolio Table 122. Meabco A/S Recent Development Table 123. INSYS Therapeutics, Inc. Company Information Table 124. INSYS Therapeutics, Inc. Business Overview Table 125. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 127. INSYS Therapeutics, Inc. Recent Development Table 128. Humanetics Corporation Company Information Table 129. Humanetics Corporation Business Overview Table 130. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio Table 132. Humanetics Corporation Recent Development Table 133. GNI Group Ltd. Company Information Table 134. GNI Group Ltd. Business Overview Table 135. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio Table 137. GNI Group Ltd. Recent Development Table 138. Diffusion Pharmaceuticals Inc. Company Information Table 139. Diffusion Pharmaceuticals Inc. Business Overview Table 140. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio Table 142. Diffusion Pharmaceuticals Inc. Recent Development Table 143. Cumberland Pharmaceuticals, Inc. Company Information Table 144. Cumberland Pharmaceuticals, Inc. Business Overview Table 145. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio Table 147. Cumberland Pharmaceuticals, Inc. Recent Development Table 148. Cleveland BioLabs, Inc. Company Information Table 149. Cleveland BioLabs, Inc. Business Overview Table 150. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio Table 152. Cleveland BioLabs, Inc. Recent Development Table 153. Chrysalis BioTherapeutics, Inc. Company Information Table 154. Chrysalis BioTherapeutics, Inc. Business Overview Table 155. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 157. Chrysalis BioTherapeutics, Inc. Recent Development Table 158. Cellphire, Inc. Company Information Table 159. Cellphire, Inc. Business Overview Table 160. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio Table 162. Cellphire, Inc. Recent Development Table 163. Key Raw Materials Table 164. Raw Materials Key Suppliers Table 165. Choroidal Neovascularization Drug Distributors List Table 166. Choroidal Neovascularization Drug Customers List Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Choroidal Neovascularization Drug Product Image Figure 2. Global Choroidal Neovascularization Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Choroidal Neovascularization Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Choroidal Neovascularization Drug Sales (2021-2032) & (K Units) Figure 5. Global Choroidal Neovascularization Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Choroidal Neovascularization Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. EWA-001 Image Figure 9. Entolimod Image Figure 10. DG-3 Image Figure 11. BBT-007 Image Figure 12. BB-3 Image Figure 13. AVMOC-001 Image Figure 14. Others Image Figure 15. Global Choroidal Neovascularization Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Choroidal Neovascularization Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2032) Figure 18. Global Choroidal Neovascularization Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Choroidal Neovascularization Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Others Image Figure 24. Global Choroidal Neovascularization Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Choroidal Neovascularization Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2032) Figure 27. Global Choroidal Neovascularization Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Choroidal Neovascularization Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 44. China Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Choroidal Neovascularization Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Choroidal Neovascularization Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Choroidal Neovascularization Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Choroidal Neovascularization Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Choroidal Neovascularization Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Choroidal Neovascularization Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Choroidal Neovascularization Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Choroidal Neovascularization Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Choroidal Neovascularization Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Choroidal Neovascularization Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • EWA-001
  • Entolimod
  • DG-3
  • BBT-007
  • BB-3
  • AVMOC-001
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Soligenix, Inc.
  • RxBio, Inc.
  • RedHill Biopharma Ltd.
  • RDD Pharma Ltd.
  • ProCertus BioPharm Inc.
  • Pluristem Therapeutics Inc.
  • PharmaIN Corporation
  • Onconova Therapeutics, Inc.
  • Neumedicines Inc.
  • Meabco A/S
  • INSYS Therapeutics, Inc.
  • Humanetics Corporation
  • GNI Group Ltd.
  • Diffusion Pharmaceuticals Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cleveland BioLabs, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cellphire, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Choroidal Neovascularization Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Choroidal Neovascularization Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Choroidal Neovascularization Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Choroidal Neovascularization Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Choroidal Neovascularization Drug Market Dynamics
  1. 2.1 Choroidal Neovascularization Drug Industry Trends
  2. 2.2 Choroidal Neovascularization Drug Industry Drivers
  3. 2.3 Choroidal Neovascularization Drug Industry Opportunities and Challenges
  4. 2.4 Choroidal Neovascularization Drug Industry Restraints
3 Choroidal Neovascularization Drug Market by Manufacturers
  1. 3.1 Global Choroidal Neovascularization Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Choroidal Neovascularization Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Choroidal Neovascularization Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Choroidal Neovascularization Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Choroidal Neovascularization Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Choroidal Neovascularization Drug Manufacturers, Product Type & Application
  7. 3.7 Global Choroidal Neovascularization Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Choroidal Neovascularization Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Choroidal Neovascularization Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Choroidal Neovascularization Drug Tier 1, Tier 2, and Tier 3
4 Choroidal Neovascularization Drug Market by Type
  1. 4.1 Choroidal Neovascularization Drug Type Introduction
  2. 4.1.1 EWA-001
  3. 4.1.2 Entolimod
  4. 4.1.3 DG-3
  5. 4.1.4 BBT-007
  6. 4.1.5 BB-3
  7. 4.1.6 AVMOC-001
  8. 4.1.7 Others
  9. 4.2 Global Choroidal Neovascularization Drug Sales by Type
  10. 4.2.1 Global Choroidal Neovascularization Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Choroidal Neovascularization Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Choroidal Neovascularization Drug Revenue by Type
  14. 4.3.1 Global Choroidal Neovascularization Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Choroidal Neovascularization Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2032)
5 Choroidal Neovascularization Drug Market by Application
  1. 5.1 Choroidal Neovascularization Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Choroidal Neovascularization Drug Sales by Application
  6. 5.2.1 Global Choroidal Neovascularization Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Choroidal Neovascularization Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Choroidal Neovascularization Drug Revenue by Application
  10. 5.3.1 Global Choroidal Neovascularization Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Choroidal Neovascularization Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2032)
6 Global Choroidal Neovascularization Drug Sales by Region
  1. 6.1 Global Choroidal Neovascularization Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Choroidal Neovascularization Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Choroidal Neovascularization Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Choroidal Neovascularization Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Choroidal Neovascularization Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Choroidal Neovascularization Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Choroidal Neovascularization Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Choroidal Neovascularization Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Choroidal Neovascularization Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Choroidal Neovascularization Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Choroidal Neovascularization Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Choroidal Neovascularization Drug Revenue by Region
  1. 7.1 Global Choroidal Neovascularization Drug Revenue by Region
  2. 7.1.1 Global Choroidal Neovascularization Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Choroidal Neovascularization Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Choroidal Neovascularization Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Choroidal Neovascularization Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Choroidal Neovascularization Drug Revenue (2021-2032)
  8. 7.2.2 North America Choroidal Neovascularization Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Choroidal Neovascularization Drug Revenue (2021-2032)
  11. 7.3.2 Europe Choroidal Neovascularization Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Choroidal Neovascularization Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Choroidal Neovascularization Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Choroidal Neovascularization Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Choroidal Neovascularization Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Company
  2. 8.1.1 Eli Lilly and Company Company Information
  3. 8.1.2 Eli Lilly and Company Business Overview
  4. 8.1.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio
  6. 8.1.5 Eli Lilly and Company Recent Developments
  7. 8.2 Soligenix, Inc.
  8. 8.2.1 Soligenix, Inc. Company Information
  9. 8.2.2 Soligenix, Inc. Business Overview
  10. 8.2.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio
  12. 8.2.5 Soligenix, Inc. Recent Developments
  13. 8.3 RxBio, Inc.
  14. 8.3.1 RxBio, Inc. Company Information
  15. 8.3.2 RxBio, Inc. Business Overview
  16. 8.3.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio
  18. 8.3.5 RxBio, Inc. Recent Developments
  19. 8.4 RedHill Biopharma Ltd.
  20. 8.4.1 RedHill Biopharma Ltd. Company Information
  21. 8.4.2 RedHill Biopharma Ltd. Business Overview
  22. 8.4.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  24. 8.4.5 RedHill Biopharma Ltd. Recent Developments
  25. 8.5 RDD Pharma Ltd.
  26. 8.5.1 RDD Pharma Ltd. Company Information
  27. 8.5.2 RDD Pharma Ltd. Business Overview
  28. 8.5.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  30. 8.5.5 RDD Pharma Ltd. Recent Developments
  31. 8.6 ProCertus BioPharm Inc.
  32. 8.6.1 ProCertus BioPharm Inc. Company Information
  33. 8.6.2 ProCertus BioPharm Inc. Business Overview
  34. 8.6.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio
  36. 8.6.5 ProCertus BioPharm Inc. Recent Developments
  37. 8.7 Pluristem Therapeutics Inc.
  38. 8.7.1 Pluristem Therapeutics Inc. Company Information
  39. 8.7.2 Pluristem Therapeutics Inc. Business Overview
  40. 8.7.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio
  42. 8.7.5 Pluristem Therapeutics Inc. Recent Developments
  43. 8.8 PharmaIN Corporation
  44. 8.8.1 PharmaIN Corporation Company Information
  45. 8.8.2 PharmaIN Corporation Business Overview
  46. 8.8.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio
  48. 8.8.5 PharmaIN Corporation Recent Developments
  49. 8.9 Onconova Therapeutics, Inc.
  50. 8.9.1 Onconova Therapeutics, Inc. Company Information
  51. 8.9.2 Onconova Therapeutics, Inc. Business Overview
  52. 8.9.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  54. 8.9.5 Onconova Therapeutics, Inc. Recent Developments
  55. 8.10 Neumedicines Inc.
  56. 8.10.1 Neumedicines Inc. Company Information
  57. 8.10.2 Neumedicines Inc. Business Overview
  58. 8.10.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio
  60. 8.10.5 Neumedicines Inc. Recent Developments
  61. 8.11 Meabco A/S
  62. 8.11.1 Meabco A/S Company Information
  63. 8.11.2 Meabco A/S Business Overview
  64. 8.11.3 Meabco A/S Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Meabco A/S Choroidal Neovascularization Drug Product Portfolio
  66. 8.11.5 Meabco A/S Recent Developments
  67. 8.12 INSYS Therapeutics, Inc.
  68. 8.12.1 INSYS Therapeutics, Inc. Company Information
  69. 8.12.2 INSYS Therapeutics, Inc. Business Overview
  70. 8.12.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  72. 8.12.5 INSYS Therapeutics, Inc. Recent Developments
  73. 8.13 Humanetics Corporation
  74. 8.13.1 Humanetics Corporation Company Information
  75. 8.13.2 Humanetics Corporation Business Overview
  76. 8.13.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio
  78. 8.13.5 Humanetics Corporation Recent Developments
  79. 8.14 GNI Group Ltd.
  80. 8.14.1 GNI Group Ltd. Company Information
  81. 8.14.2 GNI Group Ltd. Business Overview
  82. 8.14.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio
  84. 8.14.5 GNI Group Ltd. Recent Developments
  85. 8.15 Diffusion Pharmaceuticals Inc.
  86. 8.15.1 Diffusion Pharmaceuticals Inc. Company Information
  87. 8.15.2 Diffusion Pharmaceuticals Inc. Business Overview
  88. 8.15.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio
  90. 8.15.5 Diffusion Pharmaceuticals Inc. Recent Developments
  91. 8.16 Cumberland Pharmaceuticals, Inc.
  92. 8.16.1 Cumberland Pharmaceuticals, Inc. Company Information
  93. 8.16.2 Cumberland Pharmaceuticals, Inc. Business Overview
  94. 8.16.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio
  96. 8.16.5 Cumberland Pharmaceuticals, Inc. Recent Developments
  97. 8.17 Cleveland BioLabs, Inc.
  98. 8.17.1 Cleveland BioLabs, Inc. Company Information
  99. 8.17.2 Cleveland BioLabs, Inc. Business Overview
  100. 8.17.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio
  102. 8.17.5 Cleveland BioLabs, Inc. Recent Developments
  103. 8.18 Chrysalis BioTherapeutics, Inc.
  104. 8.18.1 Chrysalis BioTherapeutics, Inc. Company Information
  105. 8.18.2 Chrysalis BioTherapeutics, Inc. Business Overview
  106. 8.18.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  108. 8.18.5 Chrysalis BioTherapeutics, Inc. Recent Developments
  109. 8.19 Cellphire, Inc.
  110. 8.19.1 Cellphire, Inc. Company Information
  111. 8.19.2 Cellphire, Inc. Business Overview
  112. 8.19.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio
  114. 8.19.5 Cellphire, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Choroidal Neovascularization Drug Value Chain Analysis
  2. 9.1.1 Choroidal Neovascularization Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Choroidal Neovascularization Drug Production Mode & Process
  6. 9.2 Choroidal Neovascularization Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Choroidal Neovascularization Drug Distributors
  9. 9.2.3 Choroidal Neovascularization Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst